Drug Profile
TNP 2092
Alternative Names: CBR-2092; TNP-2092; TNP-2092 Capsule; TNP-2092 IV; TNP-2092 POLatest Information Update: 26 Oct 2022
Price :
$50
*
At a glance
- Originator Cumbre Pharmaceuticals
- Developer TenNor Therapeutics
- Class Antibacterials; Cyclopropanes; Fluorinated hydrocarbons; Irritable bowel syndrome therapies; Piperidines; Quinolizines; Rifamycins
- Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase inhibitors; DNA-directed RNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Bacterial infections; Hepatic encephalopathy; Skin and soft tissue infections
- Phase I Helicobacter infections
- Clinical Phase Unknown Irritable bowel syndrome
Most Recent Events
- 12 Jul 2022 TenNor Therapeutics completes a phase I trial (In volunteers) in USA (IV) (NCT05074134)
- 29 Jun 2022 TenNor Therapeutics completes a phase I trial for Bacterial infections in USA (IV) (NCT04294862)
- 22 Jun 2022 Efficacy, safety and pharmacokinetics data from a phase Ib/IIa trial in hepatic encephalopathy presented at the International Liver Congress 2022 (ILC-2022)